PEAK6’s Corvus Pharmaceuticals CRVS Stock Holding History

PEAK6’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	+14,225	New	+$197K	﹤0.01%	2256

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PEAK6's CRVS Position: Q2 2026 in Review

PEAK6 opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 14,225 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #2256 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

PEAK6 held 14,225 shares of Corvus Pharmaceuticals worth $213K as of Q2 2026.
Corvus Pharmaceuticals was a new PEAK6 position in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2256 holding.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.